Abstract
Abstract Background and Aims Although there is considerable research on the role of proteinuria in the progression of chronic kidney disease, a direct comparison between biopsy-diagnosed glomerular disease (GD) patients presenting with nephrotic syndrome (NS) and those with nephrotic range proteinuria (NRP) is lacking. Our study aims to bridge this gap by comparing the long-term outcomes of patients with NS and NRP. Method We conducted a unicentric retrospective study on 240 kidney biopsy-proven GD patients (median age 50 years, 65% men, median eGFR 58 mL/min, median proteinuria 6.0 g/24 h), tracked from 2010-2015 until end-stage kidney disease (ESKD), death, or study end in January 2022. Results The median follow-up was 8.8 years. Diagnoses were predominantly nonproliferative (53%), proliferative (25%) nephropathies, diabetic nephropathy (12%), and paraprotein diseases (10%). NS was observed in 141 (59%) patients, presenting more frequently with arterial hypertension (61 vs 43%, p 0.001), higher eGFR (64.9 vs 51.5 mL/min, p 0.001), increased proteinuria (6.4 vs 5.4g/24 h, p 0.01), and dyslipidemia (serum cholesterol 316 vs 251 mg/dL, p 0.001; serum triglycerides 226 vs 184 mg/dL, p 0.001) than NRP patients. NRP patients more often had proliferative (30 vs 22%) GD and diabetic nephropathy (22 vs 5%) ; their renal chronicity score was higher (2 vs 0, p 0.001). ESKD endpoint occurred in 35% NS and 39% NRP patients (p 0.4). The cohort's mean kidney survival time was 8.2 years. In multivariate analysis, NS (HR 1.79, 95% CI: 1.09, 2.94), lower eGFR (HR 0.97, 95% CI: 0.96, 0.98), higher renal chronicity score (HR 1.12, 95% CI: 1.02, 1.23), and diabetic nephropathy (Ref, p 0.001) were associated with ESKD. 64 patients (27%) died, 73% post-kidney replacement therapy initiation, mostly from cardiovascular disease (63%). Mortality between proteinuria forms showed no difference. Multivariate analysis found lower eGFR (HR 0.98, 95% CI: 0.97, 0.99), higher Charlson comorbidity score (HR 1.38, 95% CI: 1.17, 1.64), and diabetic nephropathy (Ref, p 0.01) associated with mortality. Conclusion Our study found no difference in all-cause mortality between NS and NRP in glomerular diseases. However, adjusted analysis revealed poorer kidney survival for NS patients, emphasizing the need for personalized management to improve renal prognosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.